Results 71 to 80 of about 213,311 (303)

Does Medicare Part D Protect the Elderly from Financial Risk? [PDF]

open access: yes
The Medicare Modernization Act of 2003 added the Part D prescription drug benefit to the Medicare program. This addition, which became effective in 2006, increased Medicare program costs by more than 10 percent in order to provide, for the first time ...
Gary V. Engelhardt, Jonathan Gruber
core   +1 more source

Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Evaluate performance of the Predicting Risk of Cardiovascular Disease Events (PREVENT) calculator in rheumatoid arthritis (RA). Methods Patients with RA were matched up to 10 controls on age, sex, and enrollment year using National Veterans Health Administration, Medicare, and National Death Index data (2006–2020).
Tate M. Johnson   +13 more
wiley   +1 more source

Benzodiazepine prescribing patterns among Medicare providers, 2017 to 2023

open access: yesFrontiers in Medicine
IntroductionTo determine whether benzodiazepine (BZD) prescriptions in older adults (>65) generally adhere to the Beers Criteria of the American Geriatrics Society, and whether the likelihood of prescribing an average of > 30 days per beneficiary ...
Olivia Silvernail   +4 more
doaj   +1 more source

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

open access: yesArthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon   +2 more
wiley   +1 more source

Prescription Drug Coverage and Elderly Medicare Spending [PDF]

open access: yes
The introduction of Medicare Part D has generated interest in the cost of providing drug coverage to the elderly. Of paramount importance -- often unaccounted for in budget estimates -- are the salutary effects that increased prescription drug use might ...
Baoping Shang, Dana P. Goldman
core  

How Disease Burden Influences Medication Patterns for Medicare Beneficiaries: Implications for Policy [PDF]

open access: yes, 2008
Provides benchmarks for assessing the quality of pharmaceutical care under the Medicare Part D prescription drug benefit. Examines how the beneficiaries?
Bruce C. Stuart
core  

Essential work, invisible workers: The role of digital curation in COVID‐19 Open Science

open access: yesJournal of the Association for Information Science and Technology, Volume 76, Issue 4, Page 703-717, April 2025.
Abstract In this paper, we examine the role digital curation practices and practitioners played in facilitating open science (OS) initiatives amid the COVID‐19 pandemic. In Summer 2023, we conducted a content analysis of available information regarding 50 OS initiatives that emerged—or substantially shifted their focus—between 2020 and 2022 to address ...
Irene V. Pasquetto   +2 more
wiley   +1 more source

Medicare Part B and Part D drug eligibility for center for Medicare and Medicaid Services price negotiation under the Inflation Reduction Act: estimates using 2016–2019 data

open access: yesJournal of Pharmaceutical Policy and Practice
Background To reduce Medicare prescription drug expenditures, the 2022 Inflation Reduction Act (IRA) allows the Centers for Medicare & Medicaid Services (CMS) to directly negotiate with drug manufacturers on Medicare prices of high-expenditure drugs ...
Omar Qureshi   +2 more
doaj   +1 more source

The Commonwealth Fund/National Opinion Research Center Survey of Retiree Health Benefits, 2005: A Chartbook [PDF]

open access: yes, 2007
Analyzes the state of retiree health benefits, based on a survey of public and private employers. Looks at the Medicare Part D Prescription Drug Benefit, Governmental Accounting Standards Board regulations, and past and future changes to retiree ...
Heidi Whitmore   +2 more
core  

Current evidence and insights on single vs. double dose of basiliximab in adult solid organ transplant recipients: A systematic review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this systematic review was to assess all available clinical data regarding the use of a single dose of basiliximab in solid organ transplantation compared to the standard double dosage, with particular interest in efficacy, safety and cost‐savings.
Alessio Provenzani   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy